Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis

被引：0
|
作者：
April W. Armstrong
Ahmed M. Soliman
Keith A. Betts
Yan Wang
Yawen Gao
Vassilis Stakias
Luis Puig
机构：
[1] University of Southern California,Department of Dermatology, Keck School of Medicine
[2] AbbVie,Department of Dermatology, Hospital de la Santa Creu i Sant Pau
[3] Inc.,undefined
[4] Analysis Group,undefined
[5] Inc.,undefined
[6] AbbVie,undefined
[7] Inc.,undefined
[8] Universitat Autònoma de Barcelona,undefined
来源：
Dermatology and Therapy | 2022年 / 12卷
关键词：
Long-term benefit–risk profile; Risankizumab; Bimekizumab; Ixekizumab; Network meta-analysis; Moderate-to-severe plaque psoriasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：167 / 184
页数：17
相关论文
共 50 条
  • [41] Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis
    Aljefri, Yara E.
    Ghaddaf, Abdullah A.
    Alkhunani, Tala A.
    Alkhamisi, Taif A.
    Alahmadi, Rana A.
    Alamri, Awadh M.
    Alraddadi, Ali A.
    DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [42] Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
    Fahrbach, Kyle
    Sarri, Grammati
    Phillippo, David M.
    Neupane, Binod
    Martel, Samantha E.
    Kiri, Sandeep
    Reich, Kristian
    DERMATOLOGY AND THERAPY, 2021, 11 (06) : 1965 - 1998
  • [43] Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
    Kyle Fahrbach
    Grammati Sarri
    David M. Phillippo
    Binod Neupane
    Samantha E. Martel
    Sandeep Kiri
    Kristian Reich
    Dermatology and Therapy, 2021, 11 : 1965 - 1998
  • [44] Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
    Schmitt, J.
    Rosumeck, S.
    Thomaschewski, G.
    Sporbeck, B.
    Haufe, E.
    Nast, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 274 - 303
  • [45] Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
    Armstrong, April W.
    Betts, Keith A.
    Signorovitch, James E.
    Sundaram, Murali
    Li, Junlong
    Ganguli, Arijit X.
    Wu, Eric Q.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (07) : 1325 - 1333
  • [46] COMPARATIVE EFFICACY OF BIMEKIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
    Armstrong, A.
    Reich, K.
    Warren, R. B.
    Taieb, V
    Fahrbach, K.
    Kazmierska, P.
    Betts, M.
    Neupane, B.
    Kiri, S.
    Gordon, K.
    VALUE IN HEALTH, 2021, 24 : S14 - S14
  • [47] A NETWORK META-ANALYSIS OF RANDOMIZED, CONTROLLED TRIALS OF USTEKINUMAB AND ADALIMUMAB FOR MODERATE-TO-SEVERE PSORIASIS
    Odom, D.
    Brogan, A.
    Talbird, S. E.
    Schenkel, B.
    VALUE IN HEALTH, 2013, 16 (03) : A112 - A112
  • [48] Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice
    Duffin, K. Callis
    Yeung, H.
    Takeshita, J.
    Krueger, G. G.
    Robertson, A. D.
    Troxel, A. B.
    Shin, D. B.
    Van Voorhees, A. S.
    Gelfand, J. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (03) : 672 - 680
  • [49] Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis
    Umezawa, Y.
    Nakagawa, H.
    Niiro, H.
    Ootaki, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) : 1957 - 1960
  • [50] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
    Gordon, K. B.
    Lebwohl, M.
    Papp, K. A.
    Bachelez, H.
    Wu, J. J.
    Langley, R. G.
    Blauvelt, A.
    Kaplan, B.
    Shah, M.
    Zhao, Y.
    Sinvhal, R.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
12345